Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.48 |
| ▸ | CALML3 | P27482 | 7/20 | 0.42 |
| ▸ | MAOB | P27338 | 5/20 | 0.41 |
| ▸ | F10 | P00742 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SDHA | P31040 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6161325 | 0.87 | MAOA (0.47) | MAOACALML3MAOBF10LMNA | |
| SCHEMBL6162164 | 0.86 | MAOA (0.42) | MAOACALML3MAOBF10LMNA | |
| SCHEMBL6162599 | 0.85 | MAOA (0.53) | MAOACALML3MAOBF10LMNA | |
| SCHEMBL8118953 | 0.84 | MAOA (0.50) | MAOACALML3MAOBF10LMNA | |
| SCHEMBL8109073 | 0.83 | MAOA (0.47) | MAOACALML3MAOBF10LMNA | |
| SCHEMBL5739768 | 0.83 | MAOA (0.46) | MAOACALML3MAOBF10 | |
| SCHEMBL6164118 | 0.82 | MAOA (0.48) | MAOACALML3MAOBF10 | |
| SCHEMBL5215517 | 0.82 | MAOA (0.48) | MAOACALML3MAOBF10 | |
| SCHEMBL6163072 | 0.82 | MAOA (0.48) | MAOACALML3MAOBF10 | |
| SCHEMBL8118062 | 0.82 | MAOA (0.48) | MAOACALML3MAOBF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0939632-B1 | NON-PEPTIDYL VASOPRESSIN V1a ANTAGONISTS | LILLY CO ELI (US) | 2005-10-05 | — | — | EP | disclosed |
| EP-0984947-B8 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN CO LLC (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20020049187-A1 | Non-peptidyl vasopressin V1a antagonists | BRUNS ROBERT F (US) | 2002-04-25 | — | — | US | disclosed |
| US-6204260-B1 | 2-(AZETIDIN-2-ON-1-YL)ACETIC ACID DERIVATIVES | ELI LILLY AND COMPANY | 2001-03-20 | — | — | US | disclosed |
| EP-0984947-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN COMPANY (US) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054161-A9 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | UPJOHN CO (US) | 1999-04-08 | — | — | WO | disclosed |
| WO-1998054161-A1 | OXAZOLIDINONE ANTIBACTERIAL AGENTS HAVING A THIOCARBONYL FUNCTIONALITY | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049187-A1 | Non-peptidyl vasopressin V1a antagonists | AVPR1A, AVPR2, AVPR1B | MAOA 2324/4885CALML3 3377/4885MAOB 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.